These include hepatic Insr down-regulation, reduced insulin signaling and development of insulin resistance [96], impaired glucose tolerance, BW gain, dyslipidemia, liver fat accumulation and increased risk of NAFLD/NASH [15, 97]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.